# Tomohide Tamura

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tomohide-tamura/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,850 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 68 |
| i10-index | 251 |
| Last Known Institution | St. Luke's International Hospital |
| OpenAlex ID | https://openalex.org/A5105411153 |
| ORCID iD | https://orcid.org/0000-0003-3601-8889 |
| Works | 518 |

## Researcher papers

- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan](https://scholariq.org/papers/randomized-phase-iii-study-of-cisplatin-plus-irinotecan-versus-carboplatin-plus/)
- [CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study](https://scholariq.org/papers/ch5424802-ro5424802-for-patients-with-alk-rearranged-advanced-non-small-cell/)
- [Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data](https://scholariq.org/papers/carboplatin-or-cisplatin-based-chemotherapy-in-first-line-treatment-of-small/)
- [Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-trial-of-ipilimumab-combined-with-paclitaxel-and-carboplatin-in/)
- [Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-v-15-32-of-gefitinib-versus-docetaxel-in-previously-treated/)
- [The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer](https://scholariq.org/papers/the-clinical-relevance-of-the-mir-197-cks1b-stat3-mediated-pd-l1-network-in/)
- [Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer](https://scholariq.org/papers/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-treatment/)
- [Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/reliability-of-small-biopsy-samples-compared-with-resected-specimens-for-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [St. Luke's International Hospital](https://scholariq.org/institutions/st-luke-s-international-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.